FLT3LG - a biomarker reflecting clinical responses to the immunogenic cell death inducer oxaliplatin
The fms-related tyrosine kinase 3 (FLT3) ligand (FLT3LG) binds to FLT3 on dendritic cells to stimulate their differentiation and expansion, hence facilitating tumor antigen cross-presentation and anticancer immune responses. A recent study by Abrahamsson et al. demonstrates that, in patients receivi...
Main Authors: | Jonathan G. Pol, Julie Le Naour, Guido Kroemer |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-01-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2020.1755214 |
Similar Items
-
Dynamical Boolean Modeling of Immunogenic Cell Death
by: Andrea Checcoli, et al.
Published: (2020-11-01) -
Tumor-intrinsic determinants of immunogenic cell death modalities
by: Samuel T Workenhe, et al.
Published: (2021-01-01) -
Therapeutic implications of immunogenic cell death in human cancer
by: Fabio ePalombo, et al.
Published: (2014-01-01) -
The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy
by: Francisco J. Cueto, et al.
Published: (2021-03-01) -
Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity
by: María Julia Lamberti, et al.
Published: (2020-03-01)